vs
Frontdoor, Inc.（FTDR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Frontdoor, Inc.的1.7倍（$772.1M vs $451.0M），Revvity净利率更高（12.7% vs 9.1%，领先3.6%），Frontdoor, Inc.同比增速更快（5.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $114.0M），过去两年Revvity的营收复合增速更高（9.0% vs -8.8%）
Frontdoor, Inc.是领先的家庭服务与保障平台，主要面向美国市场运营。其提供可定制的家庭保修计划，覆盖家电、暖通空调、管道、电气系统的维修更换，同时支持用户按需对接经预先审核的本地服务商，满足住宅维护及维修需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FTDR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$451.0M
营收增速更快
FTDR
高出0.0%
5.9%
净利率更高
RVTY
高出3.6%
9.1%
自由现金流更多
RVTY
多$47.8M
$114.0M
两年增速更快
RVTY
近两年复合增速
-8.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $451.0M | $772.1M |
| 净利润 | $41.0M | $98.4M |
| 毛利率 | 55.0% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 9.1% | 12.7% |
| 营收同比 | 5.9% | 5.9% |
| 净利润同比 | 10.8% | 3.9% |
| 每股收益（稀释后） | $0.57 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTDRRVTY
| Q1 26 | $451.0M | — | ||
| Q4 25 | $432.0M | $772.1M | ||
| Q3 25 | $618.0M | $698.9M | ||
| Q2 25 | $617.0M | $720.3M | ||
| Q1 25 | $426.0M | $664.8M | ||
| Q4 24 | $383.0M | $729.4M | ||
| Q3 24 | $540.0M | $684.0M | ||
| Q2 24 | $542.0M | $691.7M |
净利润FTDRRVTY
| Q1 26 | $41.0M | — | ||
| Q4 25 | $1.0M | $98.4M | ||
| Q3 25 | $106.0M | $46.7M | ||
| Q2 25 | $111.0M | $53.9M | ||
| Q1 25 | $37.0M | $42.2M | ||
| Q4 24 | $9.0M | $94.6M | ||
| Q3 24 | $100.0M | $94.4M | ||
| Q2 24 | $92.0M | $55.4M |
毛利率FTDRRVTY
| Q1 26 | 55.0% | — | ||
| Q4 25 | 49.3% | — | ||
| Q3 25 | 57.1% | 53.6% | ||
| Q2 25 | 57.7% | 54.5% | ||
| Q1 25 | 55.2% | 56.5% | ||
| Q4 24 | 48.0% | — | ||
| Q3 24 | 56.7% | 56.3% | ||
| Q2 24 | 56.5% | 55.7% |
营业利润率FTDRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 14.5% | ||
| Q3 25 | 23.0% | 11.7% | ||
| Q2 25 | 23.7% | 12.6% | ||
| Q1 25 | 11.3% | 10.9% | ||
| Q4 24 | 1.6% | 16.3% | ||
| Q3 24 | 24.8% | 14.3% | ||
| Q2 24 | 22.9% | 12.4% |
净利率FTDRRVTY
| Q1 26 | 9.1% | — | ||
| Q4 25 | 0.2% | 12.7% | ||
| Q3 25 | 17.2% | 6.7% | ||
| Q2 25 | 18.0% | 7.5% | ||
| Q1 25 | 8.7% | 6.4% | ||
| Q4 24 | 2.3% | 13.0% | ||
| Q3 24 | 18.5% | 13.8% | ||
| Q2 24 | 17.0% | 8.0% |
每股收益（稀释后）FTDRRVTY
| Q1 26 | $0.57 | — | ||
| Q4 25 | $0.03 | $0.86 | ||
| Q3 25 | $1.42 | $0.40 | ||
| Q2 25 | $1.48 | $0.46 | ||
| Q1 25 | $0.49 | $0.35 | ||
| Q4 24 | $0.10 | $0.77 | ||
| Q3 24 | $1.30 | $0.77 | ||
| Q2 24 | $1.18 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $603.0M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $230.0M | $7.3B |
| 总资产 | $2.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 5.07× | — |
8季度趋势，按日历期对齐
现金及短期投资FTDRRVTY
| Q1 26 | $603.0M | — | ||
| Q4 25 | $566.0M | $919.9M | ||
| Q3 25 | $563.0M | $931.4M | ||
| Q2 25 | $562.0M | $991.8M | ||
| Q1 25 | $506.0M | $1.1B | ||
| Q4 24 | $436.0M | $1.2B | ||
| Q3 24 | $375.0M | $1.2B | ||
| Q2 24 | $419.0M | $2.0B |
总债务FTDRRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $565.0M | — | ||
| Q2 24 | $569.0M | — |
股东权益FTDRRVTY
| Q1 26 | $230.0M | — | ||
| Q4 25 | $242.0M | $7.3B | ||
| Q3 25 | $316.0M | $7.4B | ||
| Q2 25 | $254.0M | $7.6B | ||
| Q1 25 | $198.0M | $7.6B | ||
| Q4 24 | $239.0M | $7.7B | ||
| Q3 24 | $261.0M | $7.9B | ||
| Q2 24 | $214.0M | $7.9B |
总资产FTDRRVTY
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $2.2B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $1.2B | $12.8B | ||
| Q2 24 | $1.2B | $13.4B |
负债/权益比FTDRRVTY
| Q1 26 | 5.07× | — | ||
| Q4 25 | 4.73× | — | ||
| Q3 25 | 3.64× | — | ||
| Q2 25 | 4.56× | — | ||
| Q1 25 | 5.88× | — | ||
| Q4 24 | 4.90× | — | ||
| Q3 24 | 2.16× | — | ||
| Q2 24 | 2.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $114.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 25.3% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $387.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FTDRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $101.0M | $182.0M | ||
| Q3 25 | $64.0M | $138.5M | ||
| Q2 25 | $127.0M | $134.3M | ||
| Q1 25 | $124.0M | $128.2M | ||
| Q4 24 | $58.0M | $174.2M | ||
| Q3 24 | $25.0M | $147.9M | ||
| Q2 24 | $103.0M | $158.6M |
自由现金流FTDRRVTY
| Q1 26 | $114.0M | — | ||
| Q4 25 | $95.0M | $161.8M | ||
| Q3 25 | $58.0M | $120.0M | ||
| Q2 25 | $120.0M | $115.5M | ||
| Q1 25 | $117.0M | $112.2M | ||
| Q4 24 | $50.0M | $149.8M | ||
| Q3 24 | $16.0M | $125.6M | ||
| Q2 24 | $91.0M | $136.6M |
自由现金流率FTDRRVTY
| Q1 26 | 25.3% | — | ||
| Q4 25 | 22.0% | 21.0% | ||
| Q3 25 | 9.4% | 17.2% | ||
| Q2 25 | 19.4% | 16.0% | ||
| Q1 25 | 27.5% | 16.9% | ||
| Q4 24 | 13.1% | 20.5% | ||
| Q3 24 | 3.0% | 18.4% | ||
| Q2 24 | 16.8% | 19.7% |
资本支出强度FTDRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.6% | 2.4% | ||
| Q4 24 | 2.1% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.2% | 3.2% |
现金转化率FTDRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 101.00× | 1.85× | ||
| Q3 25 | 0.60× | 2.97× | ||
| Q2 25 | 1.14× | 2.49× | ||
| Q1 25 | 3.35× | 3.03× | ||
| Q4 24 | 6.44× | 1.84× | ||
| Q3 24 | 0.25× | 1.57× | ||
| Q2 24 | 1.12× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTDR
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
